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Summary
BACKGROUND  
 The study was undertaken to explore and generate information on the morbidity 
patterns in HAART Naïve HIV infected adults on oral Cotrimoxazole prophylaxis(CTXp) 
attending Mbagathi and Kenyatta National Hospitals, comprehensive care centres.
METHODS  
 A qualitative , retrospective  study design of mixed methods was used which comprised; 
Clinical data extraction and Secondary data analysis of 450 personal medical records that existed 
and which met inclusion criteria based on age, baseline CD4+ cells ≥ 350 count, non-pregnant, 
absence of active TB and on CTXp for duration of six months at the time of enrollment.
RESULTS  
 The study showed that patients in both Mbagathi district and Kenyatta National hospitals 
comprehensive care centres (CCC) had at baseline CD4+ cells range; 350-600 and later at 12 
months CD4+ cells range; 400-1500. Patients of younger age, when given CTXp, had a consistent 
high CD4+ cells count (above 1000 CD4+ cells count) while those of older age had CD4+ levels that 
were fluctuating. The median age was 31 years. In over 50% documentation, common infections 
were frequent and patients treated with essential antimicrobial drugs. We observed that CTXp 
prophylaxis may have reduced severity of infections and this could also have supported up to 60% 
of the resolved infections. The self-reported adherence to CTXp was observed as part of quality 
monitored care.
CONCLUSION  
 The findings of this study support work in a number of  literature in other studies done 
outside Kenya on CTXp not associated with a worsened progression of HIV disease. Stockouts 
should be avoided due to public health implications. Further studies may be done to find out what 
potential CTXp has on HIV infected Kenyan patients with serious threat of bacterial infections in 
conjunction with the customized highly active antiretroviral therapy (HAART).
 [Afr. J. Health Sci. 2019; 32(1):18-26]
Introduction
 Cotrimoxazole (also known as fixed-dose 
trimethoprim-sulfamethoxazole) is commonly used 
in sub-Saharan Africa because of its low cost, wide 
availability, broad-spectrum antimicrobial activity and 
it is well-tolerated (James, 2015). CTXp is an important 
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part of HIV management and a care toolkit in resource-
limited settings and where bacterial infections are 
highly prevalent and cause significant morbidity.
 Recent research show heightened focus on 
the occurrence of resistance to CTXp. Nevertheless, 
prophylaxis with this drug combination before and 
in conjunction with antiretroviral therapy reduces 
mortality, morbidity, and rates of hospitalization among 
human immunodeficiency virus (HIV) infected adults, 
pregnant women, and children predominantly by 
reducing rates of pneumonia, diarrhea, and malaria, 
including those co-infected with tuberculosis (TB) and 
HIV 
 Clearly benefit from co-trimoxazole prophylaxis 
(Anna, 2013; Jonathan, 2004). Despite varied levels 
of resistance to CTXp, evidence in literature appear to 
suggest in favor of CTXp prophylaxis to continue after 
antiretroviral therapy is initiated until there is evidence 
of immune recovery or contraindication (Davidson, 
2008). 
 In regard to ART naïve HIV infected patients 
receiving CTXp prophylaxis, little is known about 
the effects of CTXp in this population. This study is 
motivated by need to inform the practice and policy 
with evidence-based information.
Aim
 The aim of this study is to gather information 
meet three specific objectives which should be able to 
estimate the proportion of HIV infected adults on CTXp 
who get infections and require other antimicrobial 
interventions including, Dapsone; determine the 
frequency and duration of such illnesses in HIV infected 
adults on CTXp and document the diagnoses, isolated 
pathogens (where possible) and outcomes.
Study
 This study is undertaken to explore and generate 
knowledge on the morbidity patterns in antiretroviral 
therapy (HAART) naïve HIV infected adults on 
Cotrimoxazole prophylaxis alone attending Mbagathi 
and Kenyatta National hospitals CCCs. The assumption 
is to create primary data to help hypothesize for future 
controlled studies. 
The Research Question Is To Address
 What data exist in large personal medical 
records that quantify morbidity patterns in ART naïve 
HIV infected adults on CTXp alone? 
 Methods
 This study adopted a qualitative survey design 
of mixed methods. They comprised of clinical data 
extraction questionnaire of secondary data from 450 
personal medical records in the hospital.
 This files existed in the two identified sites 
which met inclusion criteria based on age, baseline 
CD4+ cells ≥ 350 count, non-pregnant, absence of active 
TB and on CTXp for a duration of six months at the time 
of enrollment. 
 The duration taken to observe morbidity 
characteristics of patients was one year between 2012 
-2013.
 Two sites were identified for their large volumes 
of  a documented follow up of patients living with HIV 
but HAART naïve HIV infected adults. 
 Personal medical records were available and 
approvals obtained from each hospital manager. At 
Mbagathi District Hospital (MDH), the target was 150 
records of ART naïve patients on CTXp. 
 At MDH, 8132 files of HIV positive patients 
were open for content and extract of data. At Kenyatta 
National Hospital (KNH), the target was 300 records of 
HAART naïve patients on CTXp. At KNH, 1424 files of 
HIV positive patients were open for content and extract 
of data. 
 Data was harmonized and cleaned for analysis. 
Continuous data was analysed using mean (SD) and 
median (IQR) where appropriate while categorical or 
binary data using proportions (n[%]). 
 Summerised data was visualised in tables and 
figures. Confidentiality was maintained. Data analysis 
was done using STATA version 11.2
.
RESULTS
  Gathering of information was to meet three 
specific objectives:
1 To estimate the proportion of HIV infected adults 
on CTXp who got infections and required other 
antimicrobial interventions including Dapsone. 
2 To determine the frequency and duration of such 
illnesses in HIV infected adults on CTXp
3 To document the diagnosis, isolated pathogens 
(where possible) and outcomes.
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OVERALL MDH KNH
Age (years) Mean (SD) 32.4 (9.0) 34.4 (9.4) 29.7 (7.7)
Median (IQR) 31 (26 to 38) 33 (28 to 40) 29 (25 to 34)
Temp (˚c) Mean (SD) 36.3 (0.5) 36.3 (0.5) -
Median (IQR) 36.4 (36.0 to 36.6) 36.4 (36.0 to 36.6) -
Gender Male: n (%) 119 (24.7) 40 (24.7) 79 (24.8)
Female: n (%) 363 (75.3) 122 (75.3) 240 (75.2)
KNH  =  Kenyatta National Hospital
MDH  =  Mbagathi District Hospital
     Median age of study population = 31 years




Mean (SD) 638.6 (248.9) 651.1 (301.1) 630.1 (215.2)
Median (IQR) 577.5 (455 to 749) 553 (439 to 780) 582 (473 to 732)
WBC (x103/µL) Mean (SD) 5.9 (1.8) 6.1 (1.8) 5.9 (1.8)
Median (IQR) 5.6 (4.7 to 7.0) 5.3 (4.7 to 7.9) 5.6 (4.7 to 6.9)
Neutrophils (%) Mean (SD) 39.2 (16.3) 38.7 (-) 39.2 (16.3)
Median (IQR) 41.4 (30.6 to 49.8) 38.7 (-) 41.5 (30.6 to 49.8)
Lymphocytes 
(%)
Mean (SD) 46.3 (13.3) 36.1 (17.1) 46.6 (13.1)
Median (IQR) 46.1 (39.5 to 54.5) 40.7 (34.0 to 48.1) 46.1 (39.7 to 54.9)
Monocytes (%) Mean (SD) 7.5 (5.4) 7.5 (5.5) 8.0 (3.5)
Median (IQR) 7.1 (3.8 to 10.0) 7.0 (3.7 to 9.9) 7.5 (6.2 to 11.4)
Basophils (%) Mean (SD) 0.9 (0.8) 2.8 (-) 0.9 (0.8)
Median (IQR) 0.8 (0.6 to 1.1) 2.8 (-) 0.8 (0.6 to 1.0)
Haemoglobin 
(g/dL)
Mean (SD) 13.3 (2.3) 12.4 (2.4) 13.3 (2.3)
Median (IQR) 13.3 (12.3 to 14.5) 13.0 (11.9 to 13.5) 13.4 (12.3 to 
14.5)
KNH                 =    Kenyatta National Hospital
MDH                =    Mbagathi District Hospital
Median CD4    =    577
Hb                    =    13.3g/dl
Table 1: Baseline demographic and body temperature characteristics
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OVERALL MDH KNH
Cure: n (%) 289 (60.0) 133 (82.1) 155 (48.6)
Missing: n (%) 174 (36.1) 19 (11.7) 155 (48.6)
Death: n (%) - - -
      * Resistant to 
antimicrobials: n (%)
- - -
• 60% documentation of the  infections 
 that was resolved
• 36% had missing documentation on 
 treated infection outcomes 
• *data on isolates and susceptibility 
 testing documentation missing except
 microscopy results  of urine in some  
 cases  
Figure 2: CD4 + cells at Baseline and   
 at 6 months
• CD4+ skewed. 
• Requisite for inclusion ≥ 350   
 CD4+cells/mm3 
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KNH    =   Kenyatta National Hospital     
MDH    =   Mbagathi District Hospital 
Figure 2: CD4+ cells at month 12
• CD4 skewed
• CD4 range 400-1500
Table 3: Treatment Outcomes
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SYSTEM ORGAN CLASS TERM MEDDRA PREFERRED TERM COUNT (N)
Blood And Lymphatic System Disorders (2) Lymphadenopathy 2
Eye Disorders (3) Conjunctivitis allergic 3
Gastrointestinal Disorders (19) Abdominal pain 4














Infections And Infestations(117) Eye infection 1
Fungal skin infection 5
Helminthic infection 1
Herpes zoster 10
Hiv peripheral neuropathy 2
Influenza 2
Lower respiratory tract infection 6
Malaria 1
Onychomycosis 1
System Organ Class Term MedDRA Preferred Term Count (n)
Table 5: Adverse Events
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INFECTIONS AND INFESTATIONS(117) ORAL CANDIDIASIS 2
Parotitis 1












Upper respiratory tract infection 13




Uraemia (1) Blood creatinine increased 1
Blood urea increased 1
Weight decreased 1
Metabolism And Nutrition Disorders(4) Decreased appetite 3
Diabetes mellitus 1
System Organ Class Term MedDRA Preferred Term Count (n)
Musculoskeletal And Connective Tissue 
Disorders(14)
ARTHRALGIA 2
Table 5: Adverse Events




Pain In Extremity 1
Neoplasms Benign, Malignant And 
Unspecified (Incl Cysts And Polyps)(1)
Uterine Leiomyoma 1
Nervous System Disorders(23) Dementia 1
Headache 14
Neuropathy Peripheral 3
Post Herpetic Neuralgia 4
Somnolence 1
Pregnancy, Puerperium And Perinatal 
Conditions(6)
Eclampsia 6
Renal And Urinary Disorders(2) Dysuria 2

















Table 5: Adverse Events
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Diagnoses Total Count (n)
Infections and infestations 117
Nervous system disorders 23
Skin and subcutaneous tissue disorders 21
Gastrointestinal disorders 19
Respiratory, thoracic and mediastinal disorders 18
Musculoskeletal and connective tissue disorders 14
Pregnancy, puerperium and perinatal conditions 6
Metabolism and nutrition disorders(4) 4
Eye disorders 3
Hypertension 2
Renal and urinary disorders 2
Neoplasms benign, malignant and unspecified 
(Incl uding cysts and polyps)
1
Uraemia 1
Table 6: summary of diagnoses
 Fig 3: CD4 count versus age




 The discussion of  the results of the study  and 
findings  relate to the three specific objectives stated in 
the introduction section: 
Objective
 1: is achieved by analyses of treatments provided other 
than Cotrimoxazole prophylaxis information (table 2, 3, 
4).
Objective 2: 
 Achieved by analysis of frequency of adverse 
events (documentation of treatments plans and drug 
adherence in Mbagathi & KNH sites (table 5)
Objective 3: 
 Achieved by a summary description of 
diagnoses (tables 6)
 Patients of younger age, when given CTXp, had 
a consistent high CD4+ cells usually above 1000 CD4 
count while those of older age had CD4 levels that were 
fluctuating.
 Large volumes of secondary data in MDH 
and KN was processed for information on morbidity 
patterns and treatment outcomes.
CONCLUSION 
  To conclude, continued CTXp is likely to be 
beneficial to all ART naïve HIV infected adults with 
baseline CD4 ≥  350cells/mm3 where ART is not 
practicable or a patient is yet to decide on starting ART. 
 It is clear that continued CTXp was not 
associated with drug induced  severity of HIV disease 
and this was supported by documentation of adherence 
to CTXp as quality of monitored care. 
 Evidently, continued intake of Cotrimoxazole 
prophylaxis can prevent severe secondary infections in 
ages 30yrs or below.  In Kenya, this age group is within 
the most affected and vulnerable to HIV transmission
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